Singapore, Singapore
Singapore, Singapore
SEARCH FILTERS
Time filter
Source Type

— This report studies the global Cancer Stem Cells (CSCs) market, analyzes and researches the Cancer Stem Cells (CSCs) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Janssen Qiagen Advanced Cell Diagnostics ApoCell Biofluidica Clearbridge Biomedics CytoTrack Celsee Fluxion Gilupi Cynvenio On-chip YZY Bio BioView Creatv MicroTech Fluidigm Ikonisys AdnaGen IVDiagnostics Miltenyi Biotec Aviva Biosciences Corporation ScreenCell Silicon Biosystems Market segment by Type, Cancer Stem Cells (CSCs) can be split into CellSearch Others Market segment by Application, Cancer Stem Cells (CSCs) can be split into Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment Some Points from Table of Content: Chapter One: Industry Overview of Cancer Stem Cells (CSCs) 1.1 Cancer Stem Cells (CSCs) Market Overview 1.1.1 Cancer Stem Cells (CSCs) Product Scope 1.1.2 Market Status and Outlook 1.2 Global Cancer Stem Cells (CSCs) Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Cancer Stem Cells (CSCs) Market by Type 1.3.1 CellSearch 1.3.2 Others 1.4 Cancer Stem Cells (CSCs) Market by End Users/Application 1.4.1 Breast Cancer Diagnosis and Treatment 1.4.2 Prostate Cancer Diagnosis and Treatment 1.4.3 Colorectal Cancer Diagnosis and Treatment 1.4.4 Lung Cancer Diagnosis and Treatment 1.4.5 Other Cancers Diagnosis and Treatment Chapter Two: Global Cancer Stem Cells (CSCs) Competition Analysis by Players 2.1 Cancer Stem Cells (CSCs) Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future Chapter Three: Company (Top Players) Profiles 3.1 Janssen 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 Qiagen 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 Advanced Cell Diagnostics 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.3.5 Recent Developments 3.4 ApoCell 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.4.5 Recent Developments 3.5 Biofluidica 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.5.5 Recent Developments 3.6 Clearbridge Biomedics 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.6.5 Recent Developments 3.7 CytoTrack 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.7.5 Recent Developments 3.8 Celsee 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.8.5 Recent Developments 3.9 Fluxion 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.9.5 Recent Developments 3.10 Gilupi 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Cancer Stem Cells (CSCs) Revenue (Value) (2012-2017) 3.10.5 Recent Developments 3.11 Cynvenio 3.12 On-chip 3.13 YZY Bio 3.14 BioView 3.15 Creatv MicroTech 3.16 Fluidigm 3.17 Ikonisys 3.18 AdnaGen 3.19 IVDiagnostics 3.20 Miltenyi Biotec 3.21 Aviva Biosciences Corporation 3.22 ScreenCell 3.23 Silicon Biosystems The Report Contains: 114 Pages. Make an enquire of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/288983 . For more information, please visit http://www.orbisresearch.com/reports/index/global-cancer-stem-cells-cscs-market-size-status-and-forecast-2022


News Article | October 2, 2017
Site: www.prnewswire.com

The CANCER-ID consortium brings together experts from academic medical centres and industry engaged in oncology research and patient care, who are working to advance cancer treatment and therapy monitoring by using circulating tumour cells (CTCs) and tumour-related DNA (ctDNA) found in blood. CANCER-ID supports a number of innovative research projects, which aim to develop clinical utility in cancer treatment and monitoring through the identification of biomarkers in blood, specifically for lung and breast cancer. Clearbridge BioMedics has developed the proprietary ClearCell® FX System, which is a label-free, enrichment and isolation platform that retrieves intact, viable CTCs from a patient's blood sample. The technology enables seamless processing of both CTCs and ctDNA from the same patient blood sample for subsequent analysis. It is currently being used in cancer research and clinical trials to better understand the underlying biology of cancer, to gain new insights into the disease and improve patient management. The ClearCell® FX System is also being used at several academic consortium partners and hospitals for research projects under CANCER-ID. "We believe that the use of liquid biopsy will play a critical role in advancing cancer diagnostics and personalised medicine. By participating in the CANCER-ID consortium, we aim to accelerate the adoption of CTC-based diagnostics in the clinic. This will ultimately lead to better patient management and improved outcomes for cancer patients," said Dr Michael Paumen, CEO Clearbridge BioMedics. "The innovative label-free ClearCell FX microfluidic technology is an important addition to the CANCER-ID repertoire of EpCam independent CTC capture assays, which enables the detection and characterization of subsets of tumor cells that undergo an epithelial mesenchymal transition," said Prof. Dr. Klaus Pantel, Scientific Coordinator of CANCER-ID and Chairman of the Department of Tumor Biology at the University Medical Centre Hamburg-Eppendorf Clearbridge BioMedics will show-case its liquid biopsy platform at two upcoming conferences, the ACTC meeting in October (www.actc2017.org) and AMP in November 2017 (www.amp.org). Clearbridge BioMedics is a clinical oncology company that enables non-invasive liquid biopsy using a label-free Circulating Tumour Cell (CTC ) enrichment platform. It is a National University of Singapore (NUS) spin-off company committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX System, using the CTChip®, is based on innovative technology that effectively isolates intact and viable CTCs from patients' blood. The system uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells to be used for cancer diagnosis and treatment monitoring. By enriching CTCs from standard blood samples, the platform allows for analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011, and the ClearCell® FX attained CE IVD in 2015. http://www.clearbridgebiomedics.com/ The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations and medicines regulators. IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115749], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. www.imi.europa.eu The text in this press release reflects Clearbridge BioMedics' views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein.


Clearbridge BioMedics hat ein proprietäres ClearCell® FX System entwickelt. Hierbei handelt es sich um eine label-freie Anreicherungs- und Isolierungsplattform, die intakte, lebensfähige CTCs aus Blutproben von Patienten isoliert. Die Technologie aktiviert die nahtlose Verarbeitung von beiden CTCs und ctDNA von ein und derselben Blutprobe eines Patienten zur weiteren Analyse. Sie wird derzeit in der Krebsforschung und in klinischen Tests verwendet, um die Biologie des Krebs besser zu verstehen, neue Einblicke in die Krankheit zu erhalten und die Patientenverwaltung zu verbessern. Das ClearCell® FX System wird von mehreren akademischen Konsortium-Partnern und Kliniken für Forschungsprojekte unter CANCER-ID verwendet. Clearbridge BioMedics ist ein klinisches Onkologie-Unternehmen, das nicht-invasive Flüssigbiopsien auf einer label-freien Anreicherungsplattform für zirkulierende Tumorzellen (CTC) ermöglicht. Es ist ein Ableger der National University of Singapore (NUS) und es setzt sich für die Revolutionierung der Krebserkennung und Patientenbehandlung ein. Das ClearCell® FX System mit dem CTChip® basiert auf innovativer Technologie, die intakte und lebensfähige CTCs effektiv aus dem Blut der Patienten isoliert. Das System verwendet inertialer Mikrofluidik für label-freie CTC-Anreicherung, um heterogene und dynamische Krebszellen herauszulösen, die zur Krebserkennung und Behandlungskontrolle verwendet werden können. Mit der Anreicherung von CTCs von gewöhnlichen Blutproben lassen sich über die Plattform Analysen der Krankheit vor, während und nach der Behandlung anstellen. Dies spielt in der heutigen Ära der Präzisionsmedizin eine zunehmend größere Rolle. Mit Sitz in Singapur zählt Clearbridge BioMedics derzeit Kunden aus Asien, Europa und Nordamerika. Das Unternehmen erhielt für ihr ClearCell® FX System bereits zahlreiche Auszeichnungen und weltweite Anerkennung. Clearbridge BioMedics erhielt 2011 das ISO 13485 Zertifikat und ClearCell® FX erhielt 2015 das CE IVD Zertifikat. http://www.clearbridgebiomedics.com/ Die IMI ist eine Partnerschaft zwischen der Europäischen Union und der europäischen Pharmabranche, in Vertretung durch die European Federation of Pharmaceutical Industries and Associations (EFPIA). Im Rahmen der IMI 2 verfügt die IMI über ein Budget von 3,3 Milliarden für den Zeitraum 2014–2024. Eine Hälfte des Betrags wird von Horizon 2020 finanziert, dem EU-Förderprogramm für Forschung und Innovation. Die andere Hälfte stammt von Großunternehmen, vorrangig Pharmaunternehmen. Diese erhalten keine EU-Förderung, sondern leisten Sach-/Dienstleistungsspenden, z. B. die Arbeitszeit ihrer Forscher oder Zugang zu Forschungseinrichtungen oder Ressourcen.


News Article | October 2, 2017
Site: www.prnewswire.com

SINGAPUR, 2 de octubre de 2017 /PRNewswire/ -- Clearbridge BioMedics ha anunciado hoy que se ha unido a CANCER-ID, un consorcio público-privado internacional cuyo objetivo es establecer protocolos estandarizados para los biomarcadores basados en sangre y su validación clínica. Fundado en...


News Article | October 2, 2017
Site: www.prnewswire.co.uk

The CANCER-ID consortium brings together experts from academic medical centres and industry engaged in oncology research and patient care, who are working to advance cancer treatment and therapy monitoring by using circulating tumour cells (CTCs) and tumour-related DNA (ctDNA) found in blood. CANCER-ID supports a number of innovative research projects, which aim to develop clinical utility in cancer treatment and monitoring through the identification of biomarkers in blood, specifically for lung and breast cancer. Clearbridge BioMedics has developed the proprietary ClearCell® FX System, which is a label-free, enrichment and isolation platform that retrieves intact, viable CTCs from a patient's blood sample. The technology enables seamless processing of both CTCs and ctDNA from the same patient blood sample for subsequent analysis. It is currently being used in cancer research and clinical trials to better understand the underlying biology of cancer, to gain new insights into the disease and improve patient management. The ClearCell® FX System is also being used at several academic consortium partners and hospitals for research projects under CANCER-ID. "We believe that the use of liquid biopsy will play a critical role in advancing cancer diagnostics and personalised medicine. By participating in the CANCER-ID consortium, we aim to accelerate the adoption of CTC-based diagnostics in the clinic. This will ultimately lead to better patient management and improved outcomes for cancer patients," said Dr Michael Paumen, CEO Clearbridge BioMedics. "The innovative label-free ClearCell FX microfluidic technology is an important addition to the CANCER-ID repertoire of EpCam independent CTC capture assays, which enables the detection and characterization of subsets of tumor cells that undergo an epithelial mesenchymal transition," said Prof. Dr. Klaus Pantel, Scientific Coordinator of CANCER-ID and Chairman of the Department of Tumor Biology at the University Medical Centre Hamburg-Eppendorf Clearbridge BioMedics will show-case its liquid biopsy platform at two upcoming conferences, the ACTC meeting in October (www.actc2017.org) and AMP in November 2017 (www.amp.org). Clearbridge BioMedics is a clinical oncology company that enables non-invasive liquid biopsy using a label-free Circulating Tumour Cell (CTC ) enrichment platform. It is a National University of Singapore (NUS) spin-off company committed to revolutionizing cancer diagnostics and patient care. The ClearCell® FX System, using the CTChip®, is based on innovative technology that effectively isolates intact and viable CTCs from patients' blood. The system uses inertial focusing microfluidics for label-free CTC enrichment, capturing heterogeneous and dynamic cancer cells to be used for cancer diagnosis and treatment monitoring. By enriching CTCs from standard blood samples, the platform allows for analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of precision medicine. Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America. The company has won numerous awards and garnered global recognition for the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011, and the ClearCell® FX attained CE IVD in 2015. http://www.clearbridgebiomedics.com/ The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations and medicines regulators. IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115749], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. www.imi.europa.eu The text in this press release reflects Clearbridge BioMedics' views and neither IMI nor the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained herein.


Le groupement CANCER-ID réunit des experts de centres hospitaliers universitaires et d'acteurs engagés dans la recherche en oncologie et les soins aux patients. Ils se consacrent à améliorer le traitement du cancer et le suivi de la thérapie à l'aide des cellules tumorales circulantes (CTC) et des fragments d'ADN tumoral (ctDNA) présents dans le sang. CANCER-ID soutient plusieurs projets de recherche innovants, qui visent à accroître l'efficacité clinique dans le traitement et le suivi du cancer grâce à l'identification des biomarqueurs sanguins, en particulier pour le cancer des poumons et du sein. Clearbridge BioMedics a mis au point le système exclusif ClearCell® FX System, une plateforme d'enrichissement et d'isolement sans marquage qui extrait des CTC intactes et viables de l'échantillon sanguin d'un patient. La technologie permet un traitement transparent des CTC et des ctDNA à partir du même échantillon sanguin d'un patient pour analyse ultérieure. Elle sert actuellement dans la recherche sur le cancer et les essais cliniques pour mieux comprendre la biologie sous-jacente du cancer, afin d'affiner la connaissance de la maladie et d'améliorer la gestion des patients. Le ClearCell® FX System est également utilisé par plusieurs partenaires universitaires du groupement et des hôpitaux pour des projets de recherche dirigés par CANCER-ID. Selon le professeur et docteur Klaus Pantel, coordinateur scientifique de CANCER-ID et président du département de biologie des tumeurs au centre hospitalier universitaire Hambourg-Eppendorf, « La technologie microfluidique sans marquage innovante ClearCell FX System est un ajout majeur au répertoire de CANCER-ID de dosages en captivité de CTC indépendants de l'EpCam. Elle permet la détection et la caractérisation de sous-groupes de cellules tumorales qui subissent une transition épithélio-mésenchymateuse. » Clearbridge BioMedics est une société d'oncologie clinique qui permet une biopsie liquide non invasive à l'aide d'une plateforme d'enrichissement de cellules tumorales circulantes (CTC) sans marquage. Il s'agit d'une entreprise dérivée de l'Université nationale de Singapour (NUS) qui se consacre à révolutionner le diagnostic du cancer et les soins aux patients. Le système ClearCell® FX System, utilisant le CTChip®, repose sur une technologie novatrice qui isole efficacement des CTC intactes et viables à partir du sang des patients. Le système utilise des microfluides à concentration inertielle pour enrichir des CTC sans marquage, en capturant des cellules cancéreuses hétérogènes et dynamiques destinées au diagnostic du cancer et au suivi du traitement. En enrichissant des CTC à partir d'échantillons sanguins standards, la plateforme permet l'analyse de la maladie avant, pendant et après le traitement, ce qui devient de plus en plus crucial dans la nouvelle ère de la médecine de précision. Basée à Singapour, la société Clearbridge BioMedics compte actuellement des clients en Asie, en Europe et en Amérique du Nord. La société a gagné de nombreux prix et est reconnue mondialement pour le système ClearCell® FX System. Clearbridge BioMedics a reçu la certification ISO 13485 en 2011 et le ClearCell® FX System a obtenu la norme CE IVD en 2015. http://www.clearbridgebiomedics.com/ L'IMI œuvre à améliorer la santé, en accélérant le développement et l'accès des patients à des médicaments innovants, en particulier dans les domaines où les besoins médicaux ou sociaux ne sont pas satisfaits. Pour ce faire, elle facilite la collaboration entre les principaux acteurs impliqués dans la recherche en matière de santé, notamment les universités, l'industrie pharmaceutique et d'autres industries, les petites et moyennes entreprises (PME), les associations de patients et les autorités de réglementation dans le domaine des médicaments.


— This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others). This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. For more information or any query mail at sales@wiseguyreports.com Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America, Middle East and Africa Market Segment by Applications, can be divided into Prostate Cancer Breast Cancer Colorectal Cancer Others There are 13 Chapters to deeply display the global Circulating Tumor Cells market. Chapter 2, to analyze the top manufacturers of Circulating Tumor Cells, with sales, revenue, and price of Circulating Tumor Cells, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cells, for each region, from 2011 to 2016; 2 Manufacturers Profiles 2.1 Janssen 2.1.1 Business Overview 2.1.2 Circulating Tumor Cells Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 Janssen Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.2 Qiagen(Adnagen) 2.2.1 Business Overview 2.2.2 Circulating Tumor Cells Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Qiagen(Adnagen) Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.3 Acousys Biodevices, Inc 2.3.1 Business Overview 2.3.2 Circulating Tumor Cells Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 Acousys Biodevices, Inc Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.4 ApoCell 2.4.1 Business Overview 2.4.2 Circulating Tumor Cells Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 ApoCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.5 Advanced Cell Diagnostics 2.5.1 Business Overview 2.5.2 Circulating Tumor Cells Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 Advanced Cell Diagnostics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.6 Fluxion Biosciences 2.6.1 Business Overview 2.6.2 Circulating Tumor Cells Type and Applications 2.6.2.1 Type 1 2.6.2.2 Type 2 2.6.3 Fluxion Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.7 Biocept 2.7.1 Business Overview 2.7.2 Circulating Tumor Cells Type and Applications 2.7.2.1 Type 1 2.7.2.2 Type 2 2.7.3 Biocept Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.8 Fluidigm 2.8.1 Business Overview 2.8.2 Circulating Tumor Cells Type and Applications 2.8.2.1 Type 1 2.8.2.2 Type 2 2.8.3 Fluidigm Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.9 Epic Sciences 2.9.1 Business Overview 2.9.2 Circulating Tumor Cells Type and Applications 2.9.2.1 Type 1 2.9.2.2 Type 2 2.9.3 Epic Sciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.10 Clearbridge Biomedics 2.10.1 Business Overview 2.10.2 Circulating Tumor Cells Type and Applications 2.10.2.1 Type 1 2.10.2.2 Type 2 2.10.3 Clearbridge Biomedics Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.11 Cynvenio 2.11.1 Business Overview 2.11.2 Circulating Tumor Cells Type and Applications 2.11.2.1 Type 1 2.11.2.2 Type 2 2.11.3 Cynvenio Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.12 CytoTrack 2.12.1 Business Overview 2.12.2 Circulating Tumor Cells Type and Applications 2.12.2.1 Type 1 2.12.2.2 Type 2 2.12.3 CytoTrack Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.13 ScreenCell 2.13.1 Business Overview 2.13.2 Circulating Tumor Cells Type and Applications 2.13.2.1 Type 1 2.13.2.2 Type 2 2.13.3 ScreenCell Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.14 Creatv Microtech 2.14.1 Business Overview 2.14.2 Circulating Tumor Cells Type and Applications 2.14.2.1 Type 1 2.14.2.2 Type 2 2.14.3 Creatv Microtech Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.15 Aviva Biosciences 2.15.1 Business Overview 2.15.2 Circulating Tumor Cells Type and Applications 2.15.2.1 Type 1 2.15.2.2 Type 2 2.15.3 Aviva Biosciences Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.16 Greiner Bio-one GmbH 2.16.1 Business Overview 2.16.2 Circulating Tumor Cells Type and Applications 2.16.2.1 Type 1 2.16.2.2 Type 2 2.16.3 Greiner Bio-one GmbH Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.17 Sysmex Corporation 2.17.1 Business Overview 2.17.2 Circulating Tumor Cells Type and Applications 2.17.2.1 Type 1 2.17.2.2 Type 2 2.17.3 Sysmex Corporation Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share 2.18 Ikonisys 2.18.1 Business Overview 2.18.2 Circulating Tumor Cells Type and Applications 2.18.2.1 Type 1 2.18.2.2 Type 2 2.18.3 Ikonisys Circulating Tumor Cells Sales, Price, Revenue, Gross Margin and Market Share For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


SINGAPORE and Santa Monica, Calif., Nov 10, 2016 /PRNewswire/ -- The John Wayne Cancer Institute (JWCI) at the St. Johns Health Center, Providence Health Systems in Santa Monica California and Singapore-based Clearbridge BioMedics today announced a research partnership to establish a Circulating Tumor Cell Center of Research Excellence (CTC CoRE). This new center builds upon JWCI's pioneering experience in CTC assessment in patients and Clearbridge BioMedics' expertise in isolating CTCs. Targeted to be set up by November 2016, the initial focus of the CTC CoRE is on melanoma, followed by epithelial cancers. JWCI envision that in the future, the center will evolve into a CLIA[1] service for testing blood biopsy samples, with the objective of supporting diagnosis, treatment monitoring, and developing personalized therapies. This CTC CoRE leverages on JWCI's molecular CTC assay development expertise from rare cells and Clearbridge Biomedics' ClearCell® FX System for unbiased, label-free enrichment of CTCs. The research carried out at the CTC CoRE aims to use defined tumor-related DNA and RNA biomarkers established at JWCI to assess patient status before and after therapy, for example, at the time of tumor resection, before and after use of specific therapeutic drugs, or for general follow-up. This may aid clinicians to monitor tumor progression and patients' response to treatment. Work carried out at this new CTC CoRE is expected to lead to validation of several assays for use under JWCI's future CLIA program, beginning with melanoma, and followed by epithelial solid tumor cancers. This is expected to eventually result in better decision-making and significant cost savings. The program allows for unbiased and label-free isolation of CTCs in a robust and reproducible manner compatible with multiple types of downstream assays used for clinical oncology translational studies. The ClearCell® FX System is one of the world's first automated CTC retrieval systems, powered by the patented CTChip® FR1 inertial microfluidics biochip. Using a label-free approach, the ClearCell® FX System retrieves wholly-intact and viable CTCs from a standard blood draw. The ClearCell® FX System provides cost-effective retrieval of CTCs proven to work with applications used in research and the clinic, such as Next Generation Sequencing (NGS), PCR, Fluorescent in-situ hybridization (FISH) and Immunofluorescence staining. "This partnership is an expansion of our long-standing collaboration with Clearbridge BioMedics. We originally began working with them in 2011, to validate the ClearCell® FX System, and we are delighted to be setting up a new CTC Core with Clearbridge BioMedics to advance the development of our assays. We hope to be able to transform this center into a CLIA service in early 2018" said Professor Dave SB Hoon, Director, Dept. Translational Molecular Medicine, JWCI. "We are honored to partner with JWCI, a leading research and treatment cancer institute. This is the second CTC CoRE that Clearbridge BioMedics has set up - the first being with the National Cancer Centre Singapore and Singapore General Hospital in 2014. Clearbridge BioMedics will continue working towards validation of clinical utility of our ClearCell® FX System, to help oncologists have access to better tools to diagnose, treat and manage cancer," said Dr Michael Paumen, CEO Clearbridge BioMedics. In 1991, the John Wayne Cancer Institute (JWCI) launched a successful affiliation with Saint John's Health Center and opened in Santa Monica, Ca. Combined with the exceptional quality of Saint John's medical staff and hospital, a unique cancer institute was created, outstanding in the areas of translational oncology research, innovative surgery oncology approaches and medical immune-oncology. JWCI is one of three cancer centers of the Providence Health Systems on the west coast of the USA consisting of 50 hospitals from Alaska to Southern California. With renowned researchers and advanced technologies, JWCI has the unique ability to quickly and effectively react, explore, and investigate life-saving cancer treatments. Developed at the Institute, the Sentinel Node Biopsy is one such treatment. Now considered the worldwide standard of care for melanoma and breast cancer, the Sentinel Node Biopsy has revolutionized treatment options by offering a minimally invasive technique to determine the spread of tumor cells. JWCI has a strong global oncology program through its multicentre trials and collaborations with many outstanding cancer centers in the world. Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. The Company is based in Singapore and has commercially launched the ClearCell Fx platform sales to clinical research centers around the globe. The Company has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX attained CE IVD in 2015. ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs), the device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies. www.clearbridgebiomedics.com [1] In accordance with the Clinical Laboratory Improvement Amendment (CLIA), the CLIA Program sets standards and issues certificates for clinical laboratory testing. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/john-wayne-cancer-institute-and-clearbridge-biomedics-announce-partnership-to-develop-circulating-tumor-cell-centre-of-research-excellence-in-the-us-300356644.html


Patent
Clearbridge Biomedics | Date: 2013-10-16

A microfluidic device is disclosed. The device comprises at least one inlet for receiving circulating tumor cells and other cells in a sample; at least one curvilinear and/or spiral channel through which the sample is caused to undergo partial or complete Dean cycles to isolate the circulating tumor cells from the other cells; and at least one outlet configured to communicate with the channel for providing the isolated circulating tumor cells. The channel is configured to provide a predetermined Force ratio based on a desired threshold cell size of the circulating tumor cells. A corresponding method of manufacturing of the device, and a related diagnostic system are also disclosed.


Patent
Clearbridge Biomedics | Date: 2014-10-16

An interface comprising: a plurality of external ports configured to fluidically communicate with a plurality of ports of a fluidic delivery platform; and a plurality of engaging conduits configured to fluidically communicate with a plurality of ports of a microfluidic biochip, wherein a tolerance of both the plurality of external ports and/or the plurality of engaging conduits is significantly tighter than a tolerance of the plurality of ports of the microfluidic biochip.

Loading Clearbridge Biomedics collaborators
Loading Clearbridge Biomedics collaborators